Prostate cancer remains a leading cause of cancer-related morbidity and mortality among men worldwide, necessitating the continuous evolution of therapeutic approaches. This review paper provides a comprehensive analysis of the latest advancements in prostate cancer treatment, highlighting innovative modalities that have the potential to significantly improve clinical outcomes. We systematically explore emerging therapies including targeted molecular agents, immunotherapies, gene editing technologies, and novel drug delivery systems. The review highlights the mechanistic underpinnings and clinical trial data supporting the efficacy and safety of these approaches. Particular attention is given to the integration of precision medicine, which tailors treatment based on genetic and molecular tumor profiling, thereby enhancing therapeutic specificity and minimizing adverse effects. Additionally, we discuss the challenges and limitations associated with current novel therapies, such as resistance development and accessibility issues, alongside potential strategies to overcome these barriers. By synthesizing preclinical and clinical evidence, this paper underscores the paradigm shift from conventional treatments to personalized, mechanism-driven interventions. The review concludes with future perspectives on the role of artificial intelligence and biomarker discovery in optimizing prostate cancer management. Ultimately, this work aims to inform clinicians, researchers, and stakeholders about cutting-edge therapeutic innovations that promise to revolutionize prostate cancer care, thereby improving patient survival and quality of life.
Mary et al. (Tue,) studied this question.